The new France-based plant is expected to begin production in 2028 and manufacture more than 50 million sterile ophthalmic treatments annually, according to the companies.
The agreement covers production, quality control, stability testing, and CMC documentation at Bora’s Maple Grove, Minnesota facility to support a Phase 3 clinical trial.
